tiakis Biotech AG
- Biotech or pharma, therapeutic R&D
tiakis Biotech (private) | Anti-inflammatory – In process of raising $60M Series B to cover Ph2 trials in PAH and all required feasibility and CMC activities.
Lead asset: Tiprelestat, recombinant protein and potent reversible inhibitor of human neutrophil elastase and proteinase 3, developed as a differentiated disease modifying treatment for pulmonary arterial hypertension (PAH).
- Demonstrated reversal of vascular disease pathology and inflammation in animal models while being well tolerated in humans – excellent safety profile demonstrated in five randomized, placebo controlled clinical trials (109 patients).
- MoA supported by data from PAH patient cohorts showing increased neutrophil elastase levels and relative Tiprelestat deficiency (associated with clinical severity).
- Orphan designation in US and EU for the treatment of patients with PAH plus biologics exclusivity in the US.
- Phase 2-ready, affirmative FDA scientific advice received and in collaboration with Stanford University
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}